Cardiovascular disease and lipids. Issues and evidence for the management of dyslipidaemia in primary care.
The commonest manifestations of cardiovascular disease, namely coronary heart disease (CHD) and stroke, represent the two most common causes of death in the world today. Furthermore, cardiovascular diseases have the highest healthcare utilisation costs in most countries. Both primary and secondary p...
Auteur principal: | Hobbs, F |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2003
|
Documents similaires
-
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
par: article Editorial
Publié: (2020-09-01) -
Effective management of dyslipidaemia among patients with cardiovascular risk: updated recommendations on identification and follow-up.
par: Hobbs, R, et autres
Publié: (2005) -
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
par: Alberto J Lorenzatti, et autres
Publié: (2020-02-01) -
2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
par: Mach, F, et autres
Publié: (2019) -
Biochemical effects of statins on lipid parameters among newly diagnosed dyslipidaemia subjects in primary care
par: Meor Anuar Shuhaili, Meor Fairuz Rizal, et autres
Publié: (2018)